

**Figure S2. Statistical analysis**

NB - bold P value &lt; 0.05 \*

Fig 1C (i)

[Ribavirin] ( $\mu\text{M}$ )	HRSV infection (n=4)	$\pm$ SEM	P-value
Mock	0%	0%	
H2O	100%	0%	
10	64%	13%	0.056575291
20	48%	22%	<b>0.014637204</b>
40	27%	11%	<b>9.12565E-05</b>
80	7%	4%	<b>8.76743E-08</b>

Fig 2A

[DIDS] ( $\mu\text{M}$ )	HRSV infection (n=3)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
10	38%	16%	<b>0.01849495</b>
20	28%	10%	<b>0.002247572</b>
30	23%	9%	<b>0.001244719</b>
40	17%	5%	<b>6.29142E-05</b>
50	14%	4%	<b>4.41482E-05</b>

Fig 2B

[NPPB] ( $\mu\text{M}$ )	HRSV infection (n=4)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
40	57%	4%	<b>4.46039E-05</b>
60	35%	6%	<b>3.03231E-05</b>
80	15%	3%	<b>1.59212E-07</b>
100	5%	2%	<b>4.14935E-09</b>

Fig 2C

[R+IAA-94] ( $\mu\text{M}$ )	HRSV infection (n=3)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
10	89%	10%	0.334510806
15	97%	8%	0.699962848
20	105%	8%	0.605070188
25	92%	1%	<b>0.000125389</b>

Fig 3A

[CFTR(inh)-172] ( $\mu\text{M}$ )	HRSV infection (n=3)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
10	95%	4%	0.267042416
15	83%	18%	0.37752906
20	84%	13%	0.274045678
25	91%	3%	0.054221636

Fig 3B

[Chromanol 293B] ( $\mu\text{M}$ )	HRSV infection (n=3)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
20	96%	2%	0.148440081
30	113%	2%	<b>0.00124868</b>
40	108%	6%	0.248905321
50	111%	5%	0.083345039

Fig 3C

[Glibenclamide] ( $\mu\text{M}$ )	HRSV infection (n=3)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
10	84%	11%	0.19888495
20	99%	7%	0.933901547
30	92%	27%	0.781366014
40	90%	24%	0.6955903

Fig 4B

[CaCCinh-A01] ( $\mu\text{M}$ )	HRSV infection (n=4)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
5	83%	5%	<b>0.01106311</b>
10	81%	6%	<b>0.01513399</b>
20	70%	8%	<b>0.008862589</b>
30	58%	8%	<b>0.001907044</b>
40	40%	10%	<b>0.001084016</b>

Fig 4C

[Niflumic acid] ( $\mu\text{M}$ )	HRSV infection (n=4)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
10	74%	8%	<b>0.017043297</b>
20	49%	4%	<b>7.12008E-06</b>
30	26%	3%	<b>7.34332E-07</b>
40	6%	2%	<b>6.07815E-09</b>

Fig 4D

[Talniflumate] ( $\mu\text{M}$ )	HRSV infection (n=4)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
10	84%	7%	0.068624187
20	60%	4%	<b>0.000106183</b>
30	45%	7%	<b>0.000271721</b>
40	25%	10%	<b>0.000253502</b>

Fig 4E

[Tannic acid] ( $\mu\text{M}$ )	HRSV infection (n=4)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
5	102%	22%	0.943551776
10	60%	16%	<b>0.043897183</b>
15	23%	4%	<b>1.60841E-06</b>
20	9%	6%	<b>3.55868E-06</b>

Fig 5A

[T16Ainh-A01] ( $\mu\text{M}$ )	HRSV infection (n=4)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
5	103%	6%	0.637873932
10	84%	7%	0.063298134
20	30%	11%	<b>0.000624893</b>
30	21%	10%	<b>0.000225154</b>

Fig 5B

[MONNA] ( $\mu\text{M}$ )	HRSV infection (n=4)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
5	101%	6%	0.856907048
10	89%	5%	0.0633896
20	78%	4%	<b>0.001902963</b>
30	34%	11%	<b>0.000914403</b>

Fig 5E (ii)

Drug treatment	Norm HRSV-G (n=3)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
H <sub>2</sub> O	100%	0%	
Ribavirin	84%	14%	0.31645321
CaCCinh-A01	120%	26%	0.482665103
T16Ainh-A01	133%	22%	0.210016952
MONNA	137%	32%	0.31072787

Fig 5F

P-value (vs solvent control)				
	CaCCinhA01	T16AinhA01	MONNA	Ribavirin
MOI 0.1	3.74853E-05	2.84969E-05	0.005330362	0.011855105
MOI 0.5	0.000158912	5.30424E-05	0.001419678	0.006063957
MOI 1	3.17979E-05	8.68031E-06	0.006981707	0.002502494

Fig 6A

[T16Ainh-A01] ( $\mu\text{M}$ )	HRSV infection (n=3)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
10	88%	7%	<b>0.145793651</b>
20	38%	8%	<b>0.001159807</b>
30	13%	5%	<b>7.02817E-05</b>

Fig 6B

[MONNA] ( $\mu\text{M}$ )	HRSV infection (n=3)	$\pm$ SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
20	45%	5%	<b>0.000302672</b>
40	12%	3%	<b>7.60573E-06</b>

Fig 6C

[Ribavirin] ( $\mu\text{M}$ )	HRSV infection (n=3)	$\pm$ SEM	P-value
Mock	0	0	
DMSO	0.999999986	1.41077E-08	
10	0.793859886	0.152074392	0.24673625
20	0.712999902	0.06785377	<b>0.013373424</b>
40	0.420317382	0.121162206	<b>0.008747625</b>
80	0.148258481	0.080015786	<b>0.000441055</b>

**Fig 7A**

Ribavirin treatment	HRSV infection (n=3)	± SEM	P-value
Mock	0%	0%	
H <sub>2</sub> O	100%	0%	
0 hpi	15%	3%	<b>5.40812E-06</b>
3 hpi	28%	4%	<b>4.1061E-05</b>
6 hpi	41%	9%	<b>0.003327383</b>
9 hpi	63%	7%	<b>0.005205526</b>

**Fig 7B**

Ammonium chloride	HRSV infection (n=3)	± SEM	P-value
Mock	0%	0%	
H <sub>2</sub> O	100%	0%	
0 hpi	97%	2%	0.138090734
3 hpi	94%	3%	0.138696548
6 hpi	89%	6%	0.133932782
9 hpi	94%	6%	0.419262133

**Fig 7C**

Tannic acid treatment	HRSV infection (n=3)	± SEM	P-value
Mock	0%	0%	
H <sub>2</sub> O	100%	0%	
0 hpi	8%	4%	<b>2.77441E-05</b>
3 hpi	61%	3%	<b>0.000172151</b>
6 hpi	73%	7%	<b>0.01534855</b>
9 hpi	87%	2%	<b>0.001317721</b>

**Fig 7D**

NPPB treatment	HRSV infection (n=3)	± SEM	P-value
Mock	0%	0%	
H <sub>2</sub> O	100%	0%	
0 hpi	13%	4%	<b>3.89241E-05</b>
3 hpi	20%	7%	<b>0.000376239</b>
6 hpi	18%	6%	<b>0.000127559</b>
9 hpi	31%	5%	<b>0.000205059</b>

**Fig 7E**

CaCCinh-A01 treatment	HRSV infection (n=3)	± SEM	P-value
Mock	0%	0%	
H <sub>2</sub> O	100%	0%	
0 hpi	19%	6%	<b>0.000170113</b>
3 hpi	24%	3%	<b>1.48547E-05</b>
6 hpi	25%	5%	<b>0.000116391</b>
9 hpi	37%	2%	<b>4.44583E-06</b>

**Fig 7F**

Talinflumate treatment	HRSV infection (n=3)	± SEM	P-value
Mock	0%	0%	
H <sub>2</sub> O	100%	0%	
0 hpi	36%	8%	<b>0.001252441</b>
3 hpi	51%	4%	<b>0.000164702</b>
6 hpi	53%	8%	<b>0.004552312</b>
9 hpi	60%	8%	<b>0.008682141</b>

Fig 7G

T16Ainh-A01 treatment	HRSV infection (n=3)	± SEM	P-value
Mock	0%	0%	
H <sub>2</sub> O	100%	0%	
0 hpi	5%	0%	<b>4.57043E-09</b>
3 hpi	15%	6%	<b>0.000177506</b>
6 hpi	10%	3%	<b>1.31226E-05</b>
9 hpi	20%	4%	<b>2.95555E-05</b>

Fig 7H

MONNA treatment	HRSV infection (n=3)	± SEM	P-value
Mock	0%	0%	
H <sub>2</sub> O	100%	0%	
0 hpi	4%	2%	<b>3.68733E-07</b>
3 hpi	3%	1%	<b>2.22248E-07</b>
6 hpi	7%	3%	<b>5.48394E-06</b>
9 hpi	16%	4%	<b>2.29817E-05</b>

Fig 9A

[CaCCinh-A01] (μM)	IAV infection (n=3)	± SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
5	70%	6%	<b>0.006236804</b>
10	70%	5%	<b>0.002749688</b>
20	74%	5%	<b>0.00685923</b>
30	83%	6%	<b>0.042960933</b>
40	87%	7%	0.122621862

Fig 9B

[MONNA] (μM)	IAV infection (n=3)	± SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
5	73%	9%	<b>0.04495508</b>
10	70%	12%	0.069097746
20	64%	11%	<b>0.028466599</b>
30	80%	17%	0.296029284

Fig 9C

[T16Ainh-A01] (μM)	IAV infection (n=3)	± SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
5	72%	7%	<b>0.018653604</b>
10	57%	7%	<b>0.003559684</b>
20	38%	6%	<b>0.000436407</b>
30	35%	5%	<b>0.000167838</b>

Fig 9D

[Ribavirin] (μM)	Average % IAV (n=3)	± SEM	P-value
Mock	0%	0%	
DMSO	100%	0%	
10	75%	7%	<b>0.029274925</b>
20	74%	13%	0.112477732
40	58%	10%	<b>0.012958989</b>
60	14%	3%	<b>8.14213E-06</b>

## PCLS: IP-10

Fig 8A

Treatment	P-value
UV vs untreated virus	0.0043

Fig 8C

[T16Ainh-A01] ( $\mu\text{M}$ )	IP-10 fold change (n=3)	$\pm$ SEM	P-value
Mock	1	0	-
10	0.35	20.26	0.0152
20	0.07	3.87	0.0027